hat
Ou ka jwenn yon sans de sa ki lavni Crispr a ta ka kenbe ka wè nan pwogrè a nan Sangamo byosyans, ki plan trialling, yon selil somatiques modification Terapi pou VIH ak efficacité done prévu yo nan fen ane a. "Objektif lan se pou gen yon fonctionnelle guérir pou VIH,"mwen menm di sa Edward Lanphier. Sa ta kite malad sispann pran dròg antirétroviral pou yon kantite tan.
eng
A sense of what Crispr’s future might hold can be seen in the progress of Sangamo Biosciences, which is clinically trialling a somatic cell editing therapy for HIV with efficacy data anticipated by the end of the year. “The goal is to have a functional cure for HIV,” says Edward Lanphier. That would let a patient stop taking antiretroviral drugs for a number of years.